# Nona Biosciences and Lonza Enter Strategic Collaboration to Develop Best-in-Class Single-Domain Antibody-Based BBB-Crossing Technology for CNS Diseases

- Link: https://www.thailand-business-news.com/pr-news/nona-biosciences-and-lonza-enter-strategic-collaboration-to-develop-best-in-class-single-domain-antibody-based-bbb-crossing-technology-for-cns-diseases
- Published: 2026-07-02T07:05:00+07:00
- Author: PR Newswire

|   |

CAMBRIDGE, Mass., July 2, 2026 /PRNewswire/ — Nona Biosciences ("Nona"), a global
biotechnology company advancing biologics discovery and development through innovative
technology platforms, today announced a strategic collaboration with Lonza to develop
best-in-class single-domain antibody–based blood-brain barrier (BBB)-crossing technology
for central nervous system (CNS) diseases.

This collaboration will leverage Nona Biosciences’ proprietary Harbour Mice^(®) 
fully human HCAb platform to discover and develop next-generation single-domain 
antibody-based blood-brain barrier (BBB)-crossing technologies. Leveraging the platform’s
proven ability to generate fully human HCAbs and VHH binders with exceptional affinity
and developability, the partnership aims to establish a best-in-class BBB-crossing
technology capable of enabling the delivery of a diverse range of therapeutic modalities
into the central nervous system (CNS) and unlocking new opportunities in CNS drug
development and technology licensing. As part of the collaboration, Lonza’s protein
development expertise, world-leading GS Gene Expression System^(®) and GlycoConnect
^(®) bioconjugation technology will complement Nona’s platform by supporting the
optimization and broader application of selected BBB-crossing candidates.

Under the terms of the agreement, Nona is entitled to receive upfront and option
payments from Lonza. The parties will also share revenues generated from future 
licensing agreements pursuant to the collaboration.

Dr. Jingsong Wang, Chairman of Nona Biosciences, commented: "This partnership reflects
validates Nona’s platform and strategic focus in next-generation delivery technologies.
Lonza’s global reach, regulatory expertise, and commercial manufacturing capabilities
will help accelerate the advancement of our BBB-crossing-technology. Beyond technology
development, the collaboration creates opportunities for licensing, commercialization
and long-term value creation, while strengthening our position in the CNS delivery
space and supporting better outcomes for patients."

Dr. Di Hong, Chief Executive Officer of Nona Biosciences, added: "We are excited
to partner with Lonza to develop and commercialize best-in-class BBB-crossing technologies
for CNS diseases. This collaboration underscores the power and versatility of our
HCAb Harbour Mice^(®) platform and its ability to generate differentiated, fully
human single-domain binders that can tackle the most challenging delivery barriers
in drug development. By combining our platform with Lonza’s services and development
and manufacturing expertise, we are confident to offer next-generation BBB-crossing
solutions that can unlock new treatment paradigms for patients suffering from devastating
CNS disorders."

Peter Droc, Head of Licensing, Lonza, commented: "With the acquisition of IP rights
to Nona’s BBB-crossing technology and through our continued collaboration, we are
immediately enabling our customers to translate promising CNS assets into viable
therapeutics. By combining this with flexible CDMO services, we allow partners to
engage with us at any stage of their journey – from technology licensing to fully
integrated development and commercial manufacturing – reducing complexity and helping
accelerate the path to patients."

**About Nona BiosciencesNona Biosciences, a wholly owned subsidiary of HBM Holding
Limited (HKEX:02142), is a global biotechnology company committed to advancing biotherapeutic
innovation through cutting-edge technology platforms and integrated solutions. Nona
supports programs with its I to I^(®) framework, from early-stage ideas through 
preclinical research and advancement toward IND and early clinic, spanning target
validation and antibody discovery to early development.

Nona’s proprietary Harbour Mice^(®) technology platform generates fully human monoclonal
antibodies in classical two light and two heavy chain (H2L2) format, and heavy chain-
only (HCAb) format. The HCAb Harbour Mice^(®) is the world’s first fully human HCAb
transgenic mouse with clinical validation. This unique platform offers exceptional
versatility for diverse applications using fully human VH single-domain antibodies
as a plug-and-play system, including bispecific antibodies, multi-specific antibodies,
CAR-T therapies, antibody-drug conjugates (ADCs), mRNA-based therapeutics, and more.

By integrating Harbour Mice^(®), single-B cell screening technology, NonaCarFx™ (
a direct CAR-function-based screening platform), Hu-mAtrIx™ (an AI-driven drug discovery
platform), Modalities-on-Demand^(®) (a next-generation modalities solution), and
end-to-end preclinical drug development services, Nona Biosciences is dedicated 
to driving the global invention of transformative next-generation drugs. For more
information, please visit: **[www.nonabio.com](https://www.nonabio.com/)**.

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Nona Biosciences and Lonza Enter Strategic Collaboration to Develop Best-in-Class Single-Domain Antibody-Based BBB-Crossing Technology for CNS Diseases ](http://www.prnasia.com/story/archive/4996512_CN96512_0?rand=184833)